Adipokines as therapeutic targets in breast cancer treatment

Yoon Jin Cha; Ja Seung Koo

doi:10.1080/14728222.2018.1538356

Adipokines as therapeutic targets in breast cancer treatment

Yoon Jin Cha, Ja Seung Koo

Department of Pathology

Research output: Contribution to journal › Review article › peer-review

15 Citations (Scopus)

Abstract

Introduction: Adipocytes, which represent a substantial part of the tumor microenvironment in breast cancer, secrete several adipokines that affect tumorigenesis, cancer progression, metastasis, and treatment resistance via multiple signaling pathways. Areas covered: In this review, we focus on the role of leptin, adiponectin, autotaxin, and interleukin-6 in breast cancer initiation, progression, metastasis, and drug response. Furthermore, we investigated adipokines as potential targets of breast cancer-specific drugs. Expert opinion: Adipokines and adipokine receptors are deregulated in breast cancer. Adipokines play various roles in breast cancer initiation, progression, metastasis, and drug response, hence, adipokine signaling could be an effective drug target. Several clinical trials are in progress to test the efficacy of adipokine targeting agents. However, adipokines also affect metabolic homeostasis; hence, the adverse effects of the targeted drug should be investigated and addressed.

Original language	English
Pages (from-to)	941-953
Number of pages	13
Journal	Expert Opinion on Therapeutic Targets
Volume	22
Issue number	11
DOIs	https://doi.org/10.1080/14728222.2018.1538356
Publication status	Published - 2018 Nov 2

Bibliographical note

Funding Information:
This paper was funded by the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea under grant [1420080], and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology under grant [2015R1A1A1A05001209].

Funding Information:
This paper was funded by the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea under grant [1420080], and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology under grant [2015R1A1A1A05001209]. The authors deeply appreciate Dongsu Jang, medical illustrator, for his support making the Figures 1 and 2.

Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.

All Science Journal Classification (ASJC) codes

Molecular Medicine
Pharmacology
Drug Discovery
Clinical Biochemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/14728222.2018.1538356

Cite this

@article{ea254a7a81b4409d93ba9034d8afe66a,

title = "Adipokines as therapeutic targets in breast cancer treatment",

abstract = "Introduction: Adipocytes, which represent a substantial part of the tumor microenvironment in breast cancer, secrete several adipokines that affect tumorigenesis, cancer progression, metastasis, and treatment resistance via multiple signaling pathways. Areas covered: In this review, we focus on the role of leptin, adiponectin, autotaxin, and interleukin-6 in breast cancer initiation, progression, metastasis, and drug response. Furthermore, we investigated adipokines as potential targets of breast cancer-specific drugs. Expert opinion: Adipokines and adipokine receptors are deregulated in breast cancer. Adipokines play various roles in breast cancer initiation, progression, metastasis, and drug response, hence, adipokine signaling could be an effective drug target. Several clinical trials are in progress to test the efficacy of adipokine targeting agents. However, adipokines also affect metabolic homeostasis; hence, the adverse effects of the targeted drug should be investigated and addressed.",

author = "Cha, {Yoon Jin} and Koo, {Ja Seung}",

note = "Funding Information: This paper was funded by the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea under grant [1420080], and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology under grant [2015R1A1A1A05001209]. Funding Information: This paper was funded by the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea under grant [1420080], and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology under grant [2015R1A1A1A05001209]. The authors deeply appreciate Dongsu Jang, medical illustrator, for his support making the Figures 1 and 2. Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2018",

month = nov,

day = "2",

doi = "10.1080/14728222.2018.1538356",

language = "English",

volume = "22",

pages = "941--953",

journal = "Expert Opinion on Therapeutic Targets",

issn = "1472-8222",

publisher = "Informa Healthcare",

number = "11",

}

TY - JOUR

T1 - Adipokines as therapeutic targets in breast cancer treatment

AU - Cha, Yoon Jin

AU - Koo, Ja Seung

N1 - Funding Information: This paper was funded by the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea under grant [1420080], and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology under grant [2015R1A1A1A05001209]. Funding Information: This paper was funded by the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea under grant [1420080], and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology under grant [2015R1A1A1A05001209]. The authors deeply appreciate Dongsu Jang, medical illustrator, for his support making the Figures 1 and 2. Publisher Copyright: © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2018/11/2

Y1 - 2018/11/2

N2 - Introduction: Adipocytes, which represent a substantial part of the tumor microenvironment in breast cancer, secrete several adipokines that affect tumorigenesis, cancer progression, metastasis, and treatment resistance via multiple signaling pathways. Areas covered: In this review, we focus on the role of leptin, adiponectin, autotaxin, and interleukin-6 in breast cancer initiation, progression, metastasis, and drug response. Furthermore, we investigated adipokines as potential targets of breast cancer-specific drugs. Expert opinion: Adipokines and adipokine receptors are deregulated in breast cancer. Adipokines play various roles in breast cancer initiation, progression, metastasis, and drug response, hence, adipokine signaling could be an effective drug target. Several clinical trials are in progress to test the efficacy of adipokine targeting agents. However, adipokines also affect metabolic homeostasis; hence, the adverse effects of the targeted drug should be investigated and addressed.

AB - Introduction: Adipocytes, which represent a substantial part of the tumor microenvironment in breast cancer, secrete several adipokines that affect tumorigenesis, cancer progression, metastasis, and treatment resistance via multiple signaling pathways. Areas covered: In this review, we focus on the role of leptin, adiponectin, autotaxin, and interleukin-6 in breast cancer initiation, progression, metastasis, and drug response. Furthermore, we investigated adipokines as potential targets of breast cancer-specific drugs. Expert opinion: Adipokines and adipokine receptors are deregulated in breast cancer. Adipokines play various roles in breast cancer initiation, progression, metastasis, and drug response, hence, adipokine signaling could be an effective drug target. Several clinical trials are in progress to test the efficacy of adipokine targeting agents. However, adipokines also affect metabolic homeostasis; hence, the adverse effects of the targeted drug should be investigated and addressed.

UR - http://www.scopus.com/inward/record.url?scp=85056086635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056086635&partnerID=8YFLogxK

U2 - 10.1080/14728222.2018.1538356

DO - 10.1080/14728222.2018.1538356

M3 - Review article

C2 - 30332900

AN - SCOPUS:85056086635

SN - 1472-8222

VL - 22

SP - 941

EP - 953

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

IS - 11

ER -

Adipokines as therapeutic targets in breast cancer treatment

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this